Amerikanische Gesellschaft für Hirudotherapie

Microbiota Dynamics: A Key Factor in Hirudotherapy-Related Infections?

Karasartova D, Arslan-Akveran G, Sensoz S, Mumcuoglu KY, Taylan-Ozkan A (2025) · Microorganisms · n=0

RCT evidence detailTrial reference
GRADE LowCohort / case series

Study Profile

Design
experimental microbiology study using 16S rRNA V3-V4 region amplicon sequencing on the Illumina NovaSeq platform to characterize the gastrointestinal microbiota of three medicinal leech groups: long-fasting farmed leeches, recently fed farmed leeches (bovine blood), and wild specimens fed amphibian blood (Hitit University Faculty of Medicine, Turkiye; Hadassah Medical School, Hebrew University, Jerusalem, Israel; International Cyprus University)
Sample size (n)
0
Intervention
Comparative 16S rRNA metasequencing of leech mouth, pharynx, crop, and intestinal microbiota across the three leech groups; identification of environmental versus symbiotic/probiotic bacterial families and opportunistic pathogens with implications for hirudotherapy infection risk
Comparator
Within-study comparison of microbiota composition across the three leech groups; no clinical patient outcomes as comparator
Primary endpoint
Identification of bacterial families, symbiotic/probiotic populations, and opportunistic pathogens in the medicinal leech digestive tract that could pose hirudotherapy-related infection risk
Primary result
Significant microbiota differences were found across leech groups and across digestive system regions; environmental bacteria were present in all groups to varying degrees; first-time identification of certain opportunistic pathogens in the studied leech species; authors concluded that extensive screening for opportunistic pathogens should be performed on leeches intended for medical use and that long-fasting leeches from specialized farms are recommended for hirudotherapy
Follow-up duration
not applicable - cross-sectional microbiology characterization

Key Findings

  • Comprehensive 16S rRNA metasequencing of medicinal leech microbiota across fasting state, blood meal source, and farming origin
  • First-time identification of certain opportunistic pathogens in the studied leech species — direct relevance to hirudotherapy safety
  • Demonstrates that fasting state and blood meal source significantly influence leech microbiota composition
  • Provides scientific basis for the institutional recommendation that hirudotherapy use only specialized-farm long-fasting leeches
  • Reinforces the need for routine pathogen screening of leeches intended for medical use

Limitations

  • Cross-sectional microbiology characterization - does not provide patient-level outcome data
  • 16S rRNA sequencing identifies bacterial families but not strain-level pathogenicity
  • Limited sample size per leech group - inference about broader populations preliminary
  • No comparison to leeches from different geographic regions or farming standards
  • Pathogenicity of identified opportunistic organisms requires culture-based confirmation

Clinical Implications

Karasartova 2025 provides modern microbiological evidence supporting the institutional standard that medicinal leech therapy use only specialized-farm long-fasting leeches with documented microbiology screening. For US clinicians and institutions providing K040187-cleared leech therapy, the trial reinforces the importance of vendor selection (FDA-registered specialized farms), batch microbiology surveillance, and routine pathogen screening as part of an antibiotic-stewardship program. The trial complements Beka 2018 (ciprofloxacin resistance), Wilmer 2013 (Vancouver surveillance), and Reese 2015 (Greifswald infection series) in framing the contemporary leech-microbiology safety landscape.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.